Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lot-to-lot Consistency of Synflorix in Infants
NCT00307554Phase 3Completed
- Sponsor
- GSK
- Start
- Nov 2005
- Modality
- Split/Subunit Vaccines
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of 10-valent pneumococcal conjugate vaccine in pneumococcal infection (4 arms), sponsored by GSK. Primary endpoints: Antibody concentrations to pneumococcal serotypes and carrier protein PD and Percentage of subjects with antibody concentrations >= 0.20 µg/mL. Started Nov 2005; status: completed.
02
Drugs
10-valent pneumococcal conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT00307554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00307554.